Welcome to our dedicated page for NewcelX Ltd. SEC filings (Ticker: NCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NewcelX Ltd. (Nasdaq: NCEL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. NewcelX reports under the Exchange Act on Form 20-F and furnishes current reports on Form 6-K, offering investors structured insight into its operations as a Swiss clinical-stage biopharmaceutical and biotechnology company focused on neurodegenerative and metabolic diseases.
Through these filings, readers can follow key corporate events connected to the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd., which established NewcelX as a combined entity integrating cell-therapy platforms with neuroscience and small-molecule expertise. For example, a Form 6-K details the post-merger appointment of Kost Forrer Gabbay & Kasierer, a member of Ernst & Young, as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and describes the prior engagement and dismissal of CBIZ CPAs, P.C., along with references to previously disclosed material weaknesses.
On Stock Titan, NewcelX filings such as annual reports on Form 20-F, interim and event-driven Form 6-K submissions, and related exhibits can be viewed alongside AI-powered summaries. These summaries are designed to highlight essential elements of lengthy documents, helping users quickly identify information on topics like accounting firm changes, internal control disclosures, merger-related details, and other governance matters discussed in the filings.
Investors researching NCEL can use this page to monitor how NewcelX describes its business, risk factors, financial reporting framework, and post-merger integration steps over time. Real-time updates from EDGAR combined with AI-assisted overviews aim to make complex regulatory content more accessible without replacing the need to review the full original filings.
NewcelX Ltd. (NCEL), a Switzerland-incorporated biotechnology company, filed a Form D for a completed exempt offering under Rule 506(b) of Regulation D. The company offered equity securities, including common shares, warrants to purchase common shares, and the common shares issuable upon warrant exercise.
The total amount sold in the offering is $2,940,234, which the company states includes the exercise price of common shares underlying the warrants at an exercise price of $4.437 per share, with $0 remaining to be sold. No sales commissions or finders’ fees were reported. The date of first sale was July 3, 2026.
NewcelX Ltd. (NCEL), a Switzerland-based clinical-stage cell therapy company, has filed a Form F-3 to register for resale up to 694,268 Common Shares. These consist of 347,134 shares issued in a July 2026 private placement and 347,134 shares issuable upon exercise of related warrants.
The resale is by existing selling shareholders; no shares are being sold by NewcelX. NewcelX will not receive proceeds from shareholder resales, but could receive up to $1.54 million if the July 2026 warrants are exercised for cash. Its Common Shares trade on the Nasdaq Capital Market under the symbol “NCEL,” and 5,776,128 Common Shares were outstanding as of August 19, 2026.
NewcelX focuses on stem-cell-derived, off-the-shelf regenerative therapies, led by NCEL-101 for Type 1 diabetes, and also develops a DOXA small-molecule platform. The company highlights prior financings, including a $1.4 million July 2026 placement and a $1.35 million April 2026 PIPE, and reports a 2025 pro forma net loss of $6.716 million. NewcelX cautions that resale and future issuances could pressure its share price and dilute existing holders.
NewcelX Ltd. entered into definitive securities purchase agreements for a private placement financing with certain accredited investors. Investors agreed to purchase 347,134 common shares, or pre-funded warrants in lieu thereof, at $4.033 per share, plus common warrants to purchase up to 347,134 common shares at an exercise price of $4.437 per share. The common warrants have a five-year term. The transaction is expected to yield $1.4 million in gross proceeds, with approximately $1.5 million of additional gross proceeds possible upon full cash exercise of the common warrants.
NewcelX plans to use the net proceeds, together with its current cash and a previously announced $25 million equity line, primarily to advance NCEL-101, its lead Type 1 Diabetes program in collaboration with Eledon Pharmaceuticals, and for working capital and general corporate purposes. Closing is expected on or about August 14, 2026, subject to customary closing conditions. The company agreed for 60 days not to enter agreements to issue additional common shares or equivalents or to file registration statements, subject to customary exceptions, and will use reasonable best efforts to file a resale registration statement within 45 calendar days. The securities are being issued in reliance on Section 4(a)(2) and Rule 506(b) of Regulation D to accredited investors or qualified institutional buyers, without general solicitation.
NewcelX Ltd. entered into securities purchase agreements for a $1.4 million private equity financing. The company will sell 347,134 common shares at $4.033 per share, a 20% premium to the July 30, 2026 closing price, plus warrants to purchase 347,134 additional common shares at an exercise price of $4.437, equal to 132% of that closing price. The financing, which includes participation from existing shareholders, is expected to close on or about August 14, 2026, subject to customary closing conditions.
NewcelX plans to use the proceeds, together with its current cash and a previously announced $25 million equity line, primarily to advance NCEL-101, its stem-cell-derived Type 1 Diabetes program with Eledon Pharmaceuticals, and for working capital and general corporate purposes. The securities are being issued in a private placement under Section 4(a)(2) and Regulation D and are not registered under the Securities Act, so resale in the United States requires an effective registration statement or a valid exemption. Forward-looking statements highlight risks including regulatory outcomes, clinical development uncertainties, substantial doubt about the company’s ability to continue as a going concern, and its ability to maintain Nasdaq listing.
NewcelX Ltd. reports that the Brazilian Patent and Trademark Office has issued Patent Number 112018010946-0, protecting the manufacturing process for its lead stem-cell-derived therapy candidate NCEL-101 for type 1 diabetes through November 2036. This Brazil patent complements the existing U.S. patent portfolio and is described as strengthening NewcelX’s global intellectual property position and potential partnering opportunities.
The company highlights Brazil as a major type 1 diabetes market, with about 500,000 people living with the disease and prevalence growing at an estimated 4.4% annually. NewcelX also notes a recently completed FDA Type B Pre-IND meeting for NCEL-101 in combination with Eledon’s anti-CD40L antibody, tegoprubart, which it says provides a regulatory pathway toward initiating clinical trials, while risk disclosures reiterate that its financial position raises substantial doubt about its ability to continue as a going concern.
NewcelX Ltd., a clinical-stage biotechnology company focused on regenerative cell therapies for type 1 diabetes, reported the appointment of world‑renowned diabetes researcher Dr. Camillo Ricordi to its Scientific Advisory Board.
The company links this hire to its recently completed FDA Type B Pre‑IND meeting for its lead program, NCEL‑101, which it says provided a clear regulatory pathway toward starting clinical trials. Dr. Ricordi brings extensive experience in islet transplantation, stem cell–derived islet replacement and immune modulation, and will advise on NewcelX’s biologic replacement strategy, regenerative medicine platform and collaboration with Eledon Pharmaceuticals.
The press release reiterates standard forward‑looking statement cautions and highlights risks such as regulatory uncertainty, clinical trial timing, technology adoption, intellectual property protection, Nasdaq listing compliance and the company’s financial position, which it states raises substantial doubt about its ability to continue as a going concern.
NewcelX Ltd. reports a successful Type B Pre-IND meeting with the U.S. FDA for its lead cell therapy candidate NCEL-101, aimed at treating type 1 diabetes in combination with Eledon Pharmaceuticals’ anti-CD40L antibody, tegoprubart. FDA feedback aligned with NewcelX’s proposed development strategy, including its Chemistry, Manufacturing, and Controls processes and preclinical program, allowing the company to move toward IND-enabling activities and planning a first clinical trial. NCEL-101 is built on a human pluripotent stem cell platform and is designed as a scalable, off-the-shelf islet cell replacement therapy, supported by existing clinical experience with tegoprubart in transplant patients.
NewcelX Ltd. reported that it held its Annual General Shareholders’ Meeting on June 30, 2026. Shareholders approved all proposals presented at the meeting, each receiving the required majority. The proposals were previously detailed in the notice and invitation furnished on June 5, 2026 as an exhibit to an earlier report.
The company also stated that this report is incorporated by reference into its existing shelf registration statements on Form F-3, meaning those registration statements now include the information from this update.